Emmett T. Cunningham Jr., MD, PhD, MPH
With more than 20 years of experience in the biomedical and biopharmaceutical sectors, Dr. Cunningham joined Clarus in 2006 from Eyetech Pharmaceuticals, Inc. where he was the Senior Vice President of Medical Strategy. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc, and responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute. He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation.
Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit, an industry “must attend” symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Dr. Cunningham represents Clarus on the Board of Directors of Annexon Biosciences, Graybug Vision, Restoration Robotics, and SFJ Pharmaceuticals; is a Board observer for Lumos Pharma; and is on the Scientific Advisory Board of Aerie Pharmaceuticals.